SynthesisFrontiers in pharmacology2026
Short-term sleep benefits
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Given the high prevalence and clinical significance of insomnia in COPD patients, and the ongoing controversy surrounding benzodiazepine receptor positive allosteric modulators (PAMs) therapy, this study systematically evaluates the dual-temporal (short- and long-term) safety profile of PAMs through simultaneous assessment of therapeutic benefits and multidimensional risks in COPD-insomnia comorbidity. Methods: A systematic review and meta-analysis was conducted following the PRISMA guidelines. Systematic literature searches were performed in the target databases. The primary indicators for short-term efficacy and safety assessment comprised total sleep time (TST), number of awakenings, sleep efficiency, partial pressure of oxygen (PaO Results: In COPD patients, PAMs demonstrated significant short-term benefits, with notable improvements in TST (p < 0.00001), frequency of awakenings (p = 0.005), and sleep efficiency (p < 0.00001). Compared with placebo, PAMs did not increase short-term risks in terms of FEV Conclusion: In patients with COPD and comorbid insomnia, the short-term use of PAMs demonstrates therapeutic potential for improving sleep quality and enhancing quality of life, while not imposing additional respiratory burden. However, prolonged administration may potentially accelerate COPD disease progression. Clinical decisions regarding PAMs therapy for COPD patients with insomnia should be made cautiously after thorough evaluation of short-term benefits Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/recorddashboard, identifier CRD420251035164.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.